INCREASEPHARM introduction

Beijing Increasepharm Corporation Limited (Increasepharm), established in 1999 by Professor Zhang Baoxian, headquartered in Beijing, with lab area 40,000 m², pilot area 10, 000 m², manufacturing area 60 Mu, staff nearly 700 R&D personnel, 40 senior Ph.D., 90% won bachelor degree or above. Increasepharm lead in R&D of TCM, focusing on independent R&D, supplemented by CRO service, integrating R&D, pilot test, achievement transformation and industrialization.

Base on business type and regional advantage, Increasepharm has 11 wholly owned and holding subsidaries, which located in Beijing, Tianjing and Hebei, Great Bay Area (GBA) including Guangdong, Hong Kong, and Macao, and the Yangtze River Delta.

As it develops, Increasepharm has many honors and qualifications granted by governments, such as CNAS certification laboratory, Tianjin Key Laboratory of Pulmonary Administration, Guangdong Nebulization Inhalation Engineering Technology Center, Hebei Key Laboratory of TCM Nebulization Inhalation, and is preparing to apply for National Key Laboratory, Guangdong Unicorn Seed Enterprises, Beijing and Zhuhai have established postdoctoral workstations and G20 backup enterprises. At the same time, Increasepharm is recognized by China Association of TCM, World Federation of Chinese Medicine Societies and other 6 national societies, committees from these societies conduct academical research in our company.

Increasepharm has complete R & D industrial chain including 5 areas and 18 technical platforms, five advantageous clinical departments (Respiratory department, Orthopedics department, Ophthalmology department, Infection department and Oncology department) to build the company's core R & D advantages.

Culture

Chairman message

In the long history of Chinese culture, the Traditional Chinese Medicine has always been the fortune of Chinese people, which has made an indelible contribution to the prosperity of China. Zhang Zhongjing, who is referred to as the Chinese Hippocrates, stated the treatment principle in Chinese medicine “treatment based on syndrome differentiation”, which is regarded as the treasure of Chinese medicine. Since my childhood, I have a strong interest in Traditional Chinese Medicine, deeply nurtured by the culture of Traditional Chinese Medicine, driven by the responsibility of promoting Traditional Chinese Medicine, and have been committed to exploring the new direction of the development of modern Chinese medicine for more than 30 years.
As a new drug R&D institution integrating R&D design, pilot test incubation and achievement transformation, Increasepharm, which was founded in 1999, and developed for more than 20 years. The company has set up several subsidiaries in China, including five major business areas: Traditional Chinese Medicine, Chemical Medicine Innovation, Clinical Service, Pilot Scale and Production, and International Business; It has established four R&D centers for Traditional Chinese Medicine : TCM formula granules, TCM raw material source, TCM new drug, TCM classic Formula, and consistency evaluation for generic drug, and built several new preparation technology platforms.
Increasepharm has established a full chain R&D system covering project idea, preclinical research, clinical research, registration and industrialization. Moreover, it has formed a multi-business operation and management mode focusing on independent R&D and supplemented by CRO service and technical consultation. Today, Increasepharm has become one of the new drug R&D institutions with unique research strength and development potential in China.
We are down-to-earth with meticulous care, ambitious with strong sense of responsibility. In the face of challenges, we are determined; in the future, we have clear goals: keeping a foothold in Beijing, serving the whole country and taking a broad view of the world. We build quality with our integrity, establish brand with our specialty, and drive the future with innovation. In line with the tenet of "innovation-driven, excellence-aimed, integrity-based, win-win cooperation", all colleagues of Increasepharm work shoulder to shoulder, putting their enthusiasm into our common pursuit, keeping exploring and creating. Increasepharm is willing to work with you to provide you with new drug R&D and technical services with high-tech and broad market prospect, and is committed to building a national excellent brand and becoming a leading enterprise in the field of medicine.

History of development

Honors

It has won the National 863 project, 15 major new drug innovation projects listed in the "Eleventh Five Year Plan", "Twelfth Five Year Plan" and "Thirteenth Five Year Plan" of the Ministry of Science and Technology, and 24 other provincial and municipal projects.

Partners

Increasepharm has partners and customer resources all over the world, providing professional and core competitiveness for services and products separately in the pharmaceutical industry.